dsip dosage FAQ

Consider a washout period. DSIP's receptor sensitisation mechanism can induce homeostatic downregulation if sustained indefinitely. The body compensates by reducing baseline opioid receptor density. A two-week cessation period allows receptor populations to reset. Many chronic pain protocols use 8-week cycles with 2-week breaks rather than continuous administration. Alternatively, introduce cycling with low-dose naltrexone during the off-weeks to leverage opioid receptor upregulation during the rebound phase.

Discard it. DSIP is a fragile peptide. Any temperature excursion above 8°C for more than a few hours causes protein denaturation that renders the compound inactive. You can't visually detect this degradation (the solution may look unchanged), and no at-home test verifies potency. Continuing to dose with degraded peptide wastes the protocol cycle and skews any recovery data you're tracking.

DSIP can be stacked with peptides targeting different pathways. Cerebrolysin for neurotrophic support or P21 for neuroplasticity. Without direct interaction because DSIP's primary mechanism is neuroendocrine rather than receptor-mediated in the same pathways. Avoid combining with exogenous GABAergic compounds (benzodiazepines, alcohol, phenibut) during the same administration window, as the potentiation effect could produce excessive sedation or respiratory depression.

Discard the vial and reconstitute a fresh dose. DSIP loses 15–25% potency after 24 hours at 20–25°C due to peptide bond hydrolysis and tertiary structure disruption. Refrigeration (2–8°C) slows but does not eliminate this degradation. A temperature-compromised peptide may still produce mild subjective drowsiness, but polysomnographic improvements in slow-wave sleep disappear almost entirely. Reconstituted DSIP left in a travel bag, car, or non-refrigerated environment for more than 6 hours should not be used.

Verify injection timing first. DSIP administered more than two hours before sleep or during daytime hours produces minimal cortisol modulation. Shift administration to 30–60 minutes before bed and ensure doses align with your natural sleep window, not an arbitrary clock time. If timing is correct and effects remain absent, increase frequency from 3 to 4–5 doses weekly before raising individual dose. HPA recalibration responds better to sustained low-level exposure than sporadic high doses.

Increase the dose to 0.35–0.5 mg and verify injection timing—if you're dosing 30 minutes before bed instead of 90 minutes, the peptide's peak activity misses the cortisol decline window entirely. Measure waking cortisol via salivary test at 30 minutes post-wake; if it's above 15 nmol/L, your HPA axis is still overactive and requires a higher dose or earlier injection time. Some individuals are poor responders due to CRH receptor polymorphisms—genetic variations that reduce peptide binding affinity—but this represents fewer than 10% of users.

Prepare five separate vials reconstituted to five different concentrations, each optimised for the same injection volume. If your doses are 50mcg, 100mcg, 200mcg, 400mcg, and 800mcg, and you want every injection to be exactly 0.1mL, calculate the required concentration for each: 50mcg in 0.1mL = 0.5mg/mL; 100mcg = 1mg/mL; 200mcg = 2mg/mL; 400mcg = 4mg/mL; 800mcg = 8mg/mL. Use 10mg vials for all except the 800mcg dose (which requires a 20mg vial to avoid excessive dilution). Reconstitute each vial to its target concentration, label clearly with concentration and dose, and use identical 0.1mL injection volumes across all groups. This approach eliminates volume-based variability as a confounding factor. All subjects receive identical injection volumes, and the only variable is peptide concentration. It's the gold standard for dose-response research design but requires meticulous vial labelling and separate syringes for each concentration to prevent cross-contamination.

Add the remaining required peptide mass from a second vial to restore target concentration. If your protocol called for 2mL to achieve 5mg/mL (10mg vial) but you added 3mL instead, your actual concentration is 3.33mg/mL (10mg ÷ 3mL). To restore 5mg/mL, you need 15mg total peptide in 3mL (5mg/mL × 3mL = 15mg). Add 5mg from a second vial to the over-diluted solution. Final concentration becomes 5mg/mL (15mg ÷ 3mL). Never attempt to withdraw liquid from a reconstituted vial to correct concentration. The removal process introduces air and contaminants through the stopper. Alternatively, recalculate all subsequent injection volumes based on the actual concentration achieved. If you're locked into the 3.33mg/mL concentration from the error, a 250mcg dose now requires 0.075mL instead of the 0.05mL you planned (250mcg = 0.25mg; 0.25mg ÷ 3.33mg/mL = 0.075mL). Document the concentration change in your research log and maintain consistent volume measurement throughout the study to preserve dose accuracy.

Reconstitute to a lower concentration that makes the injection volume measurable with standard insulin syringes. A 20mcg dose at 2.5mg/mL concentration requires 0.008mL. Impossible to measure accurately with syringes graduated to 0.01mL. Instead, reconstitute your 5mg vial with 10mL bacteriostatic water to create 0.5mg/mL concentration. Now the 20mcg dose = 0.04mL (20mcg = 0.02mg; 0.02mg ÷ 0.5mg/mL = 0.04mL), which is four graduation marks on a 0.3mL insulin syringe. Easily measurable. Larger reconstitution volumes (10mL for a 5mg vial) reduce the number of doses per vial and require larger vial sizes to accommodate the liquid volume. Standard peptide vials are 3mL, 5mL, or 10mL capacity. Ensure your vial can physically hold the reconstitution volume before adding bacteriostatic water. Overfilling a 3mL vial creates pressure that forces solution through the stopper seal, contaminating the vial exterior and creating dosing hazards.

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

Discard it. Peptide bonds degrade irreversibly at temperatures above 8°C, and once denatured, DSIP loses bioactivity without visible change in appearance. A vial left at 20–25°C for 8+ hours is no longer therapeutically viable. Continuing to use it wastes money and introduces dosing inconsistency that makes titration impossible to assess. Lyophilised DSIP stored correctly (refrigerated before reconstitution, used within 28 days after mixing) maintains potency; temperature-excursed product does not.

Switch to a 4-nights-on, 3-nights-off cycle immediately. Tolerance in DSIP protocols manifests as reduced delta wave improvement despite maintained dosing. The same 2mg dose that initially improved deep sleep percentage stops working. Taking 2–3 consecutive nights off per week allows GABAergic receptor upregulation, which restores sensitivity. Alternatively, discontinue DSIP entirely for 1–2 weeks, then resume at your previously effective dose. Research from Pharmacology Biochemistry and Behavior (1991) found that 14-day washout periods fully restored receptor sensitivity in subjects who had developed tolerance at 5mg nightly dosing.

Increase to 1.5mg and continue for another 3–5 nights before assessing again. DSIP's mechanism relies on cumulative neurotransmitter modulation. Single-dose trials don't capture the full effect. If 1.5mg still shows no subjective improvement in sleep latency, night wakings, or morning restoration after 5 nights, titrate to 2mg. Most research subjects who respond to DSIP do so by 2–2.5mg; non-responders rarely benefit from doses above 3mg, suggesting the issue is receptor expression variability rather than insufficient dosing.

Units are not a standardized measurement for peptides. Unlike insulin, peptides lack universal unit-to-mass conversion factors. If a protocol lists doses in "units," contact the protocol author or institution for clarification on the mass equivalent. Guessing the conversion introduces error larger than any calculation mistake. Research-grade peptide suppliers like Real Peptides label vials in milligrams specifically to avoid unit ambiguity; mass-based dosing is the only reliable standard across peptide types.

Recalculate concentration using the actual volume added, not your intended volume. If you meant to add 2mL but added 3mL to a 5mg vial, your concentration is 5mg ÷ 3mL = 1.67mg/mL (1670mcg/mL) instead of 2.5mg/mL. For a 250mcg dose, you now need 250mcg ÷ 1670mcg/mL = 0.15mL instead of 0.1mL. The peptide isn't ruined. You simply have a more dilute solution requiring larger injection volumes. Do not attempt to remove excess water from the vial; contamination risk outweighs the inconvenience of recalculating.

Convert the dose to micrograms before calculating injection volume to avoid unit mismatch. A 0.5mg dose equals 500mcg (0.5mg × 1000 = 500mcg). If your concentration is 2.5mg/mL (2500mcg/mL), the injection volume is 500mcg ÷ 2500mcg/mL = 0.2mL. Mixing mg and mcg in the same calculation without conversion is the single most common cause of ten-fold dosing errors. Always convert to matching units first.

Use the same formula regardless of vial size: peptide mass (mg) ÷ diluent volume (mL) = concentration (mg/mL). For a 3mg vial reconstituted with 1.5mL bacteriostatic water: 3mg ÷ 1.5mL = 2mg/mL (2000mcg/mL). A 400mcg dose requires 400mcg ÷ 2000mcg/mL = 0.2mL. The principle doesn't change. Only the input numbers do. Verify your syringe can measure the resulting injection volume with adequate precision before finalizing your reconstitution volume choice.